|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||
| Net loss | ||||
| Aspire Biopharma Inc | ||||
| Total net loss | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Interest income on investments held in Trust Account | ||||
| Change in fair value of subscription loan | ||||
| Interest expense – debt discount | ||||
| Aspire Biopharma Inc | ||||
| Total interest expense – debt discount | ||||
| Debt discount amortized | ||||
| Initial recognition of forward purchase agreement liability | ||||
| Issuance of commitment shares under ELOC agreement | ||||
| Loss on extinguishment of debt | ||||
| Change in fair value of derivative liabilities and convertible notes | ||||
| Stock-based compensation | ||||
| Aspire Biopharma Inc | ||||
| Total stock-based compensation | ||||
| Prepaid expenses | ||||
| Aspire Biopharma Inc | ||||
| Total prepaid expenses | ||||
| Increase in current assets | ||||
| Accounts payable and accrued liabilities | ||||
| Aspire Biopharma Inc | ||||
| Total accounts payable and accrued liabilities | ||||
| Short-term loans from shareholders (net) | ||||
| Increase in current liabilities | ||||
| Due from Sponsor | ||||
| Due to affiliate | ||||
| Prepaid expenses and other current assets | ||||
| Inventories | ||||
| Accounts payable | ||||
| Accrued expenses | ||||
| Due to related party | ||||
| Other current liabilities | ||||
| NET CASH FLOWS USED IN OPERATING ACTIVITIES | ||||
| Aspire Biopharma Inc | ||||
| Total nET CASH FLOWS USED IN OPERATING ACTIVITIES | ||||
| Cash withdrawn from Trust Account in connection with redemptions | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||
| Series A Preferred stock, par value $0.0001 | ||||
| Additional paid in capital | ||||
| Issuance of common stock | ||||
| Aspire Biopharma Inc | ||||
| Total issuance of common stock | ||||
| Proceeds from recapitalization | ||||
| Redemption of ordinary shares | ||||
| Proceeds from Sponsor note | ||||
| Proceeds from issuance of convertible notes | ||||
| Repayment of convertible notes | ||||
| Transaction costs paid in connection with convertible notes | ||||
| Proceeds from notes payable - related party | ||||
| Repayment of notes payable – related party | ||||
| NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES | ||||
| Aspire Biopharma Inc | ||||
| Total nET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES | ||||
| NET CHANGE IN CASH | ||||
| Aspire Biopharma Inc | ||||
| Total nET CHANGE IN CASH | ||||
| CASH, BEGINNING OF THE YEAR | ||||
| Aspire Biopharma Inc | ||||
| Total cASH, BEGINNING OF THE YEAR | ||||
| CASH, END OF THE YEAR | ||||
| Aspire Biopharma Inc | ||||
| Total cASH, END OF THE YEAR | ||||
| Supplemental disclosure of noncash investing and financing activities: | ||||
| Deferred underwriting commissions payable charged to additional paid in capital | ||||
| Remeasurement of Class A ordinary shares to redemption value | ||||
| Sponsor shares contributed for no redemption of shares | ||||
| Conversion of Class B shares to Class A | ||||
| Accounts payable and other liabilities combined, net | ||||
| Shares issued pursuant to settlement agreement | ||||
| Issuance of shares in reverse recapitalization | ||||
| Conversion of warrants | ||||
| Conversion of convertible notes | ||||
| Issuance of shares under working capital loans and non redemption agreements | ||||
| Supplemental cashflow information: | ||||
| Cash paid for income taxes | ||||
| Note Payable addition from OID | ||||
| Cash paid for interest | ||||
Loading...
